2,178 results match your criteria Endometrial Carcinoma* Obstetrics and Gynecology


CA 125 is a better marker to differentiate endometrial cancer and abnormal uterine bleeding.

Afr Health Sci 2018 Dec;18(4):972-978

Department of Obstetrics and Gynecology, Jawaharlal Institute of Post graduate Medical Education and Research, Puducherry - 605006.

Background: Incidence of endometrial cancer in India is increasing due to lifestyle changes and obesity. As 5 year survival rate of cancer confined to uterus is good, there is need for serum tumor marker for early diagnosis. This study was designed to identify a tumor marker which differentiate endometrial carcinoma and abnormal uterine bleeding (AUB) because common presentation of endometrial carcinoma is AUB. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4314/ahs.v18i4.17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354887PMC
December 2018
1 Read

Sentinel lymph node mapping using indocyanine green in patients with uterine and cervical neoplasms: restrictions of the method.

Arch Gynecol Obstet 2019 Feb 14. Epub 2019 Feb 14.

Department of Cardiology, Institute of Mother and Child, Warsaw, Poland.

Purpose: To establish the surgical, demographic and histopathological factors associated with inaccurate sentinel lymph nodes (SLNs) identification using indocyanine green (ICG) and near-infrared (NIR) fluorescence imaging in uterine and cervical neoplasms during both open and laparoscopic surgery.

Methods: We reviewed patients with atypical endometrial hyperplasia (AEH), clinical stage I and II cervical cancer or uterine malignancies who underwent primary surgery with SLN mapping between September 2015 and January 2018. An analysis of patients' demographics, tumor factors and surgical approach was conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00404-019-05063-6DOI Listing
February 2019
1 Read

A retrospective validation study of sentinel lymph node mapping for high-risk endometrial cancer.

Arch Gynecol Obstet 2019 Feb 12. Epub 2019 Feb 12.

Medical University of Tianjin, No. 22, Qixiangtai Road, Heping District, Tianjin, China.

Objectives: To determine the feasibility and performance of sentinel lymph-node (SLN) mapping among women with high-risk endometrial cancer (EC).

Materials And Methods: Ninety-eight patients at high-risk EC were enrolled in this retrospective surgical trial from August 2016 to August 2018. All patients underwent intraoperative SLN biopsy, with ICG injection for laparoscopic staging; this was followed by pelvic and paraaortic lymphadenectomy (LAD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00404-019-05085-0DOI Listing
February 2019

A case of an endobronchial metastasis from an endometrial carcinoma.

SAGE Open Med Case Rep 2019 16;7:2050313X18823901. Epub 2019 Jan 16.

Department of Pathology, School of Medicine, Dongsan Medical Center, Keimyung University, Daegu, Korea.

A 73-year-old woman was referred to the pulmonology department for abnormal findings on chest computed tomography. She had undergone a laparoscopic staging operation including a hysterectomy, bilateral salpingo-oophorectomy, bilateral pelvic node and para-aortic node dissection, and concurrent chemo-radiation therapy for endometrial serous carcinoma stage IIIc cancer 15 months earlier. A follow-up chest computed tomography after the chemotherapy showed that the right lower lobe bronchus was obstructed, and it was necessary to differentiate a primary lung malignancy from a metastasis and secretion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2050313X18823901DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349978PMC
January 2019
1 Read

Expression of NR1H3 in endometrial carcinoma and its effect on the proliferation of Ishikawa cells in vitro.

Onco Targets Ther 2019 18;12:685-697. Epub 2019 Jan 18.

Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, Shandong, People's Republic of China,

Purpose: Our study aimed to investigate the expression of NR1H3 in endometrial carcinoma, its effect on the proliferation of endometrial carcinoma cells in vitro, and the underlying mechanism of this effect.

Materials And Methods: Immunohistochemistry of paraffin-embedded, sectioned specimens and of a tissue microarray was conducted to estimate the expression of NR1H3 (liver X receptors α: LXRα) and NR1H2 (liver X receptors β: LXRβ) in endometrial carcinoma tissues. The subcellular localization of NR1H3 in the endometrial carcinoma cell line Ishikawa was determined by immunofluorescence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S180534DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343513PMC
January 2019
2 Reads

Comparison and analysis of the clinicopathological features of SCEO and ECOM.

J Ovarian Res 2019 Jan 30;12(1):10. Epub 2019 Jan 30.

Department of Gynecology, obstetrics and gynecology hospital, Fudan university, Shanghai, 200,090, China.

Objective: The aim of our study was to evaluate and compare the differences in the clinicopathological variables and overall survival (OS) of synchronous primary cancers of the endometrium and ovary (SCEO) and endometrial cancer with ovarian metastasis (ECOM). In addition, we aimed to determine the characteristics of and effective treatments for patients with SCEO to avoid misdiagnosis and overtreatment.

Materials And Methods: A review of medical records from January 2009 to January 2017 revealed 111 patients with coexisting ovarian and endometrial carcinoma diagnosed at the Obstetrics and Gynecology Hospital of Fudan University. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13048-019-0485-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352368PMC
January 2019
1 Read

X chromosome-linked long noncoding RNA lnc-XLEC1 regulates c-Myc-dependent cell growth by collaborating with MBP-1 in endometrial cancer.

Int J Cancer 2019 Jan 30. Epub 2019 Jan 30.

Department of Genetics, Medical College of Soochow University, Suzhou 215123, China.

LncRNAs (long noncoding RNAs) are noncoding transcripts that are more than 200 nt long and have been described as the largest subclass in the noncoding transcriptome in humans. Although studies of lncRNAs in cancer have been continuing for a long time, no much has been known about X chromosome-linked lncRNAs. Here, by using RNA-seq we report the identification of a new X chromosome-linked lncRNA (lnc-XLEC1) that is aberrantly downregulated during the development of endometrial carcinoma (EC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.32166DOI Listing
January 2019
1 Read
5.085 Impact Factor

Synchronous endometrioid endometrial and ovarian carcinomas are biologically related: A clinico-pathological and molecular (next generation sequencing) study of 22 cases.

Oncol Lett 2019 Feb 20;17(2):2207-2214. Epub 2018 Dec 20.

Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 12800 Prague, Czech Republic.

The criteria for distinction between independent primary tumors and metastasis from one site to the other in synchronous endometrioid endometrial and ovarian carcinoma (SEO) has been a matter of dispute for a long time. In our study we performed a comprehensive clinico-pathological and molecular analysis of 22 cases of SEO. Based on conventional clinico-pathological criteria the cases were classified as independent primary tumors (10 cases) and metastasis from one location to the other (12 cases). Read More

View Article

Download full-text PDF

Source
http://www.spandidos-publications.com/10.3892/ol.2018.9855
Publisher Site
http://dx.doi.org/10.3892/ol.2018.9855DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341770PMC
February 2019
3 Reads

Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer.

Gynecol Oncol 2019 Jan 21. Epub 2019 Jan 21.

Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Shanghai 200011, China. Electronic address:

Objective: This study aimed to evaluate the efficacy of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young patients with endometrial atypical hyperplasia (EAH) and early stage endometrial cancer (EEC) who wished to preserve their fertility.

Methods: Patients with EAH (n = 120) or well-differentiated EEC (n = 40, FIGO stage IA, without myometrial invasion) were retrospectively included. All patients received constant oral progestin combined with hysteroscopic evaluation every 3 months until achieving complete response (CR). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.01.014DOI Listing
January 2019
1 Read

RE: prognostic factors and genes associated with endometrial cancer based on gene expression profiling and bioinformatics analysis.

Arch Gynecol Obstet 2019 Jan 22. Epub 2019 Jan 22.

Department of Interdisciplinary Program in Biomedical Science, Soonchunhyang University Graduate School, Asan, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00404-019-05049-4DOI Listing
January 2019

Two-sided role of estrogen on endometrial carcinogenesis: stimulator or suppressor?

Gynecol Endocrinol 2019 Jan 22:1-6. Epub 2019 Jan 22.

a Department of Obstetrics and Gynecology , Shinshu University School of Medicine , Matsumoto , Japan.

Endometrial carcinoma (EC) often expresses estrogen receptors (ER), and the growth of EC is stimulated by estrogen. Therefore, EC is considered to be an estrogen-dependent tumor. However, the role of estrogen in endometrial carcinogenesis is somewhat unclear because the majority of EC occurs at peri- or post menopause when serum estrogen levels are generally decreased. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/09513590.2018.1
Publisher Site
http://dx.doi.org/10.1080/09513590.2018.1549219DOI Listing
January 2019
3 Reads

Recurrence of endometrial carcinoma presenting as vulvar lesions.

Int J Gynaecol Obstet 2019 Jan 17. Epub 2019 Jan 17.

Department of Obstetrics and Gynecology, Shaare Zedek Medical Center, Hebrew University, Jerusalem, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijgo.12762DOI Listing
January 2019
1 Read

Pretreatment thrombocytosis predict poor prognosis in patients with endometrial carcinoma: a systematic review and meta-analysis.

BMC Cancer 2019 Jan 15;19(1):73. Epub 2019 Jan 15.

Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, No. 20 Section 3, Renmin South Road, Chengdu, Sichuan, 610041, People's Republic of China.

Background: Several previous studies have confirmed that thrombocytosis was related to reduced survival in many solid tumors. However, the prognostic significance of thrombocytosis in endometrial carcinoma (EC) was still controversy. Therefore, we conducted this study to assess the prognostic value of thrombocytosis in EC. Read More

View Article

Download full-text PDF

Source
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-
Publisher Site
http://dx.doi.org/10.1186/s12885-018-5264-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332560PMC
January 2019
4 Reads

Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer.

PLoS One 2019 15;14(1):e0210585. Epub 2019 Jan 15.

Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.

Objective: Better biomarkers are needed in order to identify patients with endometrial carcinoma at risk of recurrence and who may profit from a more aggressive treatment regimen. Our objective was to explore the applicability of plasma growth differentiation factor 15 (GDF-15) as a marker for recurrent disease, as well as a marker for poor prognosis and lymph node metastases.

Methods: EDTA-blood samples were obtained from 235 patients with endometrial cancer before primary surgery. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0210585PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333370PMC
January 2019
2 Reads

Fertility-preserving treatment of stage IA, well-differentiated endometrial carcinoma in young women with hysteroscopic resection and high-dose progesterone therapy.

Taiwan J Obstet Gynecol 2019 Jan;58(1):90-93

Department of Obstetrics and Gynecology, Show Chwan Memorial Hospital, Changhua, Taiwan. Electronic address:

Objective: The standard treatment for endometrial cancer is surgery with hysterectomy. However, this procedure will cause infertility in young women who desire to preserve pregnant ability. Conservative management with hormone therapy has been shown to be satisfactory in both tumor control and fertility preservation. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10284559183029
Publisher Site
http://dx.doi.org/10.1016/j.tjog.2018.11.017DOI Listing
January 2019
7 Reads

DNA ploidy status, S-phase fraction, and p53 are not independent prognostic factors for survival in endometrioid endometrial carcinoma FIGO stage I-III.

Int J Gynecol Cancer 2019 Jan 13. Epub 2019 Jan 13.

Department of Obstetrics and Gynecology, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.

Objectives: To assess the effects on relative survival of established and new prognostic factors in stage I-III grade 1-3 endometrioid endometrial carcinoma and in the subgroup of stage I grade 1-2.

Methods: This was a population-based, retrospective study including all women (n=1113) in the western Swedish healthcare region diagnosed with International Federation of Gynecology and Obstetrics (FIGO) stage I-III grade 1-3 endometrioid endometrial carcinoma in 2006-2011. Histology, grade, stage, and age were prospectively reported to the regional clinical and national cancer registers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2018-000082DOI Listing
January 2019

Unexpected malignant uterine pathology: Incidence, characteristics and outcome in a large single-center series of hysterectomies for presumed benign uterine disease.

Gynecol Oncol 2019 Jan 8. Epub 2019 Jan 8.

Department of Obstetrics and Gynecology, University of Tuebingen, Germany.

Objective: Hysterectomy is a frequently used therapeutic option for benign gynecological conditions. The purpose of this study was to investigate the incidence and characteristics of unforeseen malignant pathologies of the uterine corpus in a large population-based, single center cohort.

Methods: Patients who underwent hysterectomy for presumed benign conditions between 2003 and 2016 were identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.12.026DOI Listing
January 2019
2 Reads

The practice of universal screening for Lynch syndrome in newly diagnosed endometrial carcinoma.

Health Sci Rep 2018 Jul 14;1(7):e43. Epub 2018 Jun 14.

Department of Pathology Duke University School of Medicine Durham NC USA.

Background: Lynch syndrome (LS) accounts for 5% of all endometrial cancer (EC) cases and 4% of all lifetime risk of developing colorectal cancer. While current guidelines recommend LS screening for all patients with newly diagnosed colorectal cancer, there is no such guideline for screening patients with EC.

Discussion: This review addresses LS screening and discusses algorithms for testing patients in the setting of newly diagnosed EC. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hsr2.43
Publisher Site
http://dx.doi.org/10.1002/hsr2.43DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266449PMC
July 2018
7 Reads

Prediction of Premalignant and Malignant Endometrial Polyps by Clinical and Hysteroscopic Features.

J Minim Invasive Gynecol 2019 Jan 4. Epub 2019 Jan 4.

Department of Obstetrics and Gynecology, The Yitzhak Shamir Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (all authors).. Electronic address:

Study Objective: To investigate whether hysteroscopic features can contribute to the diagnosis of malignancy in endometrial polyps.

Design: Retrospective review.

Setting: Obstetrics and gynecology department. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmig.2018.12.018DOI Listing
January 2019
3 Reads

LINC01170 promotes the progression of endometrial carcinoma by activating the AKT pathway.

J BUON 2018 Nov-Dec;23(6):1745-1752

Department of Obstetrics and Gynecology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.

Purpose: To investigate the function of LINC01170 in the progression of endometrial carcinoma and its underlying mechanism.

Methods: The expression profiles and prognostic data of endometrial carcinoma were downloaded by GDC (genomic data commons) analysis tools. Differentially expressed long noncoding (lnc)RNAs were analyzed by the edgeR (empirical analysis of digital gene expression data in R) package. Read More

View Article

Download full-text PDF

Source
January 2019
6 Reads

Targeting cancer stem cell signature gene SMOC-2 Overcomes chemoresistance and inhibits cell proliferation of endometrial carcinoma.

EBioMedicine 2018 Dec 26. Epub 2018 Dec 26.

The Third School of Clinical Medicine, Southern Medical University, Guangzhou 510500, China; Department of Obstetrics and Gynecology, Fengxian Hospital, Southern Medical University, Shanghai 201499, China. Electronic address:

Background: Endometrial cancer is one of the most common gynecological malignancies and has exhibited an increasing incidence rate in recent years. Cancer stem cells (CSCs), which are responsible for tumor growth and chemoresistance, have been confirmed in endometrial cancer. However, it is still challenging to identify endometrial cancer stem cells to then target for therapy. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23523964183062
Publisher Site
http://dx.doi.org/10.1016/j.ebiom.2018.12.044DOI Listing
December 2018
10 Reads

MLH1 enhances the sensitivity of human endometrial carcinoma cells to cisplatin by activating the MLH1/c-Abl apoptosis signaling pathway.

BMC Cancer 2018 Dec 29;18(1):1294. Epub 2018 Dec 29.

Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, No. 107, Wenhua Xi Road, Jinan, Shandong, 250012, People's Republic of China.

Background: MLH1 plays a critical role in maintaining the fidelity of DNA replication, and defects in human MLH1 have been reported. However, the role of MLH1 in endometrial carcinoma has not been fully investigated. Therefore, we aimed to study the role of MLH1 in the sensitivity of human endometrial carcinoma cells to cisplatin. Read More

View Article

Download full-text PDF

Source
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-
Publisher Site
http://dx.doi.org/10.1186/s12885-018-5218-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311060PMC
December 2018
7 Reads

L1CAM as a Negative Prognostic Factor in Endometrioid Endometrial Adenocarcinoma FIGO Stage IA-IB.

Anticancer Res 2019 Jan;39(1):421-424

Department of Obstetrics and Gynecology, University Hospital Ostrava, Ostrava Poruba, Czech Republic.

Aims: In this study, we aimed to investigate how positivity for L1 cell adhesion molecule (L1CAM) was associated with outcome and relapse pattern in patients with Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) stage IA-IB endometrial cancer.

Materials And Methods: This retrospective study included 358 patients who underwent surgical treatment for endometrial carcinoma. Tumor samples from 312 patients (87. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13128DOI Listing
January 2019
2 Reads

Upregulation of syncytin-1 promotes invasion and metastasis by activating epithelial-mesenchymal transition-related pathway in endometrial carcinoma.

Onco Targets Ther 2019 17;12:31-40. Epub 2018 Dec 17.

Department of Clinical Medicine Laboratory, Binzhou Medical University Hospital, Binzhou 256603, Shandong, China,

Background: Endometrial carcinoma (EC) is the most common and lethal malignancy worldwide. Syncytin-1 is expressed in multiple types of cancer. However, the expression pattern and potential mechanism of syncytin-1 and its clinical significance in EC remain unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S191041DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301305PMC
December 2018
1 Read
1.342 Impact Factor

Screening of prognostic biomarkers for endometrial carcinoma based on a ceRNA network.

PeerJ 2018 10;6:e6091. Epub 2018 Dec 10.

Department of Gynaecology and Obstetrics, Shengjing hospital affiliated to China Medical University, Liaoning, China.

Objective: This study aims to reveal the regulation network of lncRNAs-miRNAs-mRNA in endometrial carcinoma (EC), to investigate the underlying mechanisms of EC occurrence and progression, to screen prognostic biomarkers.

Methods: RNA-seq and miRNA-seq data of endometrial carcinoma were downloaded from the TCGA database. Edge. Read More

View Article

Download full-text PDF

Source
https://peerj.com/articles/6091
Publisher Site
http://dx.doi.org/10.7717/peerj.6091DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292375PMC
December 2018
16 Reads

miR‑107‑5p promotes tumor proliferation and invasion by targeting estrogen receptor‑α in endometrial carcinoma.

Oncol Rep 2019 Mar 18;41(3):1575-1585. Epub 2018 Dec 18.

Department of Obstetrics and Gynecology, Shanghai General Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai 200080, P.R. China.

The aberrant expression of miR107‑5p is closely related to the development of several types of human cancers. However, the role of miR‑107‑5p in endometrial carcinoma (EC) has not been fully confirmed. In the present study, we aimed to explore the function of miR‑107‑5p in EC carcinogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/or.2018.6936DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365687PMC
March 2019
3 Reads
2.191 Impact Factor

L1 Cell Adhesion Molecule (L1CAM) expression in endometrioid endometrial carcinomas: A possible pre-operative surrogate of lymph vascular space invasion.

PLoS One 2018 17;13(12):e0209294. Epub 2018 Dec 17.

Department of Pathology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil.

Background: Risk stratification of endometrial carcinomas is primarily based on surgical staging that requires extensive retroperitoneal lymph node dissection. One of the most powerful predictor of lymph node involvement is the lymph vascular space invasion (LVSI). The objective of this study was to determine the potential of L1 Cell Adhesion Molecule (L1CAM) to predict LVSI and its association with other risk factors in endometrioid endometrial carcinomas. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0209294PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296540PMC
December 2018

High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations.

Int J Gynecol Pathol 2019 Jan;38 Suppl 1:S40-S63

Department of Pathology, Memorial Sloan Kettering Cancer Center (R.M., R.A.S.) New York University Medical Center and School of Medicine, Tisch Hospital (K.M.), New York Department of Pathology, University Hospital, Stony Brook School of Medicine, Stony Brook (C.T.), New York Department of Pathology, Oslo University Hospital, Norwegian Radium Hospital; Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway (B.D.) Department of Pathology, University of California San Diego, San Diego (O.F.) Department of Pathology, Cedars-Sinai Medical Center, Los Angeles (J.K.L.R.), California Department of Pathology, Karolinska Institutet, Stockholm, Sweden (J.A.C.) Department of Pathology, Brigham and Women's Hospital, Harvard Medical School (C.P.C.) Department of Pathology, Massachussetts General Hospital, Harvard Medical School (E.O.), Boston, Massachussetts Department of Pathology, University of British Columbia, Vancouver (C.B.G., J.A.I.) Department of Laboratory Medicine, Pathology and Medical Genetics, Royal Jubilee Hospital, Victoria (J.A.I.), BC, Canada Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas (A.M.) Department of Pathology, Hospital University Arnau de Vilanova; and Department of Pathology, Hospital University de Bellvitge, IRBLLEIDA, IDIBELL, University of Lleida, CIBERONC, Barcelona, Spain (X.M.-G.) Department of Pathology, Belfast Health and Social Care Trust, Belfast, UK (W.G.M.) Department of Pathology and Obstetrics and Gynecology, Yale School of Medicine and Yale School of Publich Health, New Haven, Connecticut (V.P.) Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland (P.N.S.) Department of Pathology, KEMH and School for Women's and Infants' Health, University of Western Australia, Perth, WA, Australia (C.J.R.S.).

This review of challenging diagnostic issues concerning high-grade endometrial carcinomas is derived from the authors' review of the literature followed by discussions at the Endometrial Cancer Workshop sponsored by the International Society of Gynecological Pathologists in 2016. Recommendations presented are evidence-based, insofar as this is possible, given that the levels of evidence are weak or moderate due to small sample sizes and nonuniform diagnostic criteria used in many studies. High-grade endometrioid carcinomas include FIGO grade 3 endometrioid carcinomas, serous carcinomas, clear cell carcinomas, undifferentiated carcinomas, and carcinosarcomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PGP.0000000000000491DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296248PMC
January 2019
29 Reads

Current Practices in the Processing, Diagnosis, and Reporting of Endometrial Carcinoma: Results of a Web-based Survey by the International Society of Gynecological Pathologists (ISGyP).

Int J Gynecol Pathol 2019 Jan;38 Suppl 1:S3-S8

Department of Pathology and Obstetrics and Gynecology, Yale School of Medicine and the Yale School of Public Health, New Haven, Connecticut (V.P.) Department of Pathology, Hospital University Arnau de Vilanova and University de Bellvitge, Irblleida, Idibell, University of Lleida, Ciberonc, Lleida, Spain (X.M.G.) Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (E.O.) Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas (A.M.) Department of Pathology, Belfast Health and Social Care Trust, Belfast, UK (W.G.M.).

There have been significant advances in our understanding of the biology and classification of endometrial carcinoma, over the last few years, and the new prediction models proposed for prognostication. To accurately diagnose and stage tumors and apply these prediction models, it is necessary that there be standardized processing of specimens, and a common understanding and usage of the diagnostic terminology of endometrial carcinoma. The International Society of Gynecological Pathologists embarked on an ambitious project to achieve this goal in 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PGP.0000000000000515DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296828PMC
January 2019

The International Society of Gynecological Pathologists (ISGyP) Endometrial Carcinoma Project.

Int J Gynecol Pathol 2019 Jan;38 Suppl 1:S1-S2

Department of Pathology, Belfast Health and Social Care Trust, Belfast, UK (W.G.M.) Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas (A.M.) Departments of Pathology, Hospital University Arnau de Vilanova and, Hospital University de Bellvitge, IRBLLEIDA, Idibell, University of Lleida, CIBERONC, Barcelona, Spain (X.M.-G.) James Homer Wright Pathology Laboratories, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts (E.O.) Department of Pathology and Obstetrics and Gynecology, Yale School of Medicine and Yale School of Public Health, New Haven, Connecticut (V.P.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PGP.0000000000000495DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296830PMC
January 2019

Outcomes of Adjuvant Therapy for Stage IA Serous Endometrial Cancer.

Cureus 2018 Sep 29;10(9):e3387. Epub 2018 Sep 29.

Radiation Oncology, Juravinski Cancer Centre-McMaster University, Hamilton, CAN.

Purpose: Serous adenocarcinoma is a rare, aggressive histologic subtype of endometrial cancer with a high rate of recurrence and a poor prognosis. The optimal adjuvant treatment for early-stage patients is unclear. Our objective was to evaluate the outcomes of stage IA serous endometrial cancers only treated at a single institution and determine whether our current approach of chemotherapy plus vaginal brachytherapy (VBT) is sufficient. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.3387DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267614PMC
September 2018
3 Reads

Molecular subtype not immune response drives outcomes in endometrial carcinoma.

Clin Cancer Res 2018 Dec 6. Epub 2018 Dec 6.

Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, University of British Columbia

Purpose: Tumors with high mutation load are thought to engender stronger immune responses which in turn promote prolonged patient survival. To investigate this, we assessed tumor-infiltrating lymphocytes (TIL) and immunosuppressive factors across the four molecular subtypes of endometrial cancer (EC), which have characteristic mutation rates ranging from low to ultra-high.

Experimental Design: 460 ECs were stratified by ProMisE (Proactive Molecular Risk Classifier in Endometrial cancer) into four molecular subtypes: mismatch repair-deficient (MMRd), POLE mutant (POLE), p53 abnormal (p53abn), and p53 wildtype (p53wt). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-3241DOI Listing
December 2018
7 Reads

Expression of programmed death-ligand 1 and hypoxia-inducible factor-1α proteins in endometrial carcinoma.

J Cancer Res Ther 2018 Dec;14(Supplement):S1063-S1069

Department of Obstetrics and Gynecology, Faculty of Medicine, Menoufia University, Al Menoufia, Egypt.

Background: Programmed death-ligand 1 (PD-L1) and hypoxia-inducible factor-1α (HIF-1α) proteins mediate major alterations of tumor microenvironment including generation of immunosuppressive microenvironment and tumor hypoxia, respectively. These alterations play a crucial role in carcinogenesis and tumor progression.

Aims: The present study was designed to investigate the correlation between the expression of PD-L1 and HIF-1α proteins and the clinicopathologic variables in endometrial carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/0973-1482.202891DOI Listing
December 2018

Oral and intrauterine progestogens for atypical endometrial hyperplasia.

Cochrane Database Syst Rev 2018 12 4;12:CD009458. Epub 2018 Dec 4.

Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, No. 20, Section Three, Ren Min Nan Lu Avenue, Chengdu, Sichuan, China, 610041.

Background: Endometrial carcinoma is the most common gynaecologic malignancy in the world and develops through preliminary stages of endometrial hyperplasia. Atypical endometrial hyperplasia suggests a significant pre-malignant state with frank progression to endometrial carcinoma, and tends to occur at a young age. Oral progestins have been used as conservative treatment in young women with atypical endometrial hyperplasia, but they are associated with poor tolerability and side effects that may limit their overall efficacy. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/14651858.CD009458.pub3
Publisher Site
http://dx.doi.org/10.1002/14651858.CD009458.pub3DOI Listing
December 2018
17 Reads

Clonal analysis revealed functional heterogeneity in cancer stem-like cell phenotypes in uterine endometrioid adenocarcinoma.

Exp Mol Pathol 2019 02 30;106:78-88. Epub 2018 Nov 30.

Departments of Pathology, Sapporo Medical University School of Medicine, South-1 West-17, Chuo-Ku, Sapporo 060-8556, Japan; CREST, Japan Science and Technology Agency, Tokyo 102-0076, Japan. Electronic address:

Uterine endometrial carcinoma is one of the common cancers in females. Cancer stem-like cells (CSCs)/cancer-initiating cells (CICs) are a small subpopulation of cancer cells that are tumorigenic and are resistant to treatments, thus they are focused as treatment targets. However, the heterogeneity of CSCs/CICs is still elusive, and we therefore analyzed CSCs/CICs at the clonal level. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yexmp.2018.11.013DOI Listing
February 2019
1 Read

Crosstalk between SOX2 and cytokine signaling in endometrial carcinoma.

Sci Rep 2018 Dec 3;8(1):17550. Epub 2018 Dec 3.

Department of Life Science and Institute of Biotechnology, National Tsing-Hua University, HsinChu, 300, Taiwan (R.O.C.).

Endometrial carcinoma is a cancer derived from oncogenesis of the regenerating uterine cavity, in which cytokine stimulation shapes cell differentiation and tissue remodeling. Expression of the stem cell factors SOX2, OCT4, NANOG, and MYC has been linked to tumor malignancy in several cancers. However, how these stem cell factors crosstalk with cytokine signaling to promote malignancy in endometrial carcinoma is still elusive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-35592-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277382PMC
December 2018

methylation promotes oncogenesis of endometrial carcinoma through LOC134466/hsa-miR-196a-5p/TAC1 axis.

Aging (Albany NY) 2018 Nov;10(11):3353-3370

Department of Oncology, The First Clinic College of Hubei University of Chinese Medicine, Wuhan 430065, Hubei, China.

To investigate possible mechanism of abnormal methylation of long non-coding RNA (lncRNA) on endometrial carcinoma (EC) progression, we detected the genome methylation profiling of endometrial carcinoma by bioinformatic analysis. Accordingly, gene was chosen for the further research. We also found that was the target gene of and miRNA, hsa-miR-196a-5p, might form a connection between and . Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/aging.101644DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286819PMC
November 2018
1 Read

Serum calcium is a novel parameter to assess metabolic syndrome in endometrial carcinoma.

J Gynecol Oncol 2019 Jan 11;30(1):e12. Epub 2018 Oct 11.

Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, China.

Objectives: To investigate the distribution of serum calcium and the relationship between serum calcium and serum metabolic parameters in endometrial carcinoma (EC) patients.

Methods: Retrospective assessment of patients diagnosed with endometrial cancer from Peking University People's Hospital from 2004 to 2009. Clinical characteristics as well as pretreatment serum calcium, albumin, fasting plasma glucose (FPG), serum triglycerides (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol (TC) value were extracted from patient records. Read More

View Article

Download full-text PDF

Source
https://ejgo.org/DOIx.php?id=10.3802/jgo.2019.30.e12
Publisher Site
http://dx.doi.org/10.3802/jgo.2019.30.e12DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304409PMC
January 2019
10 Reads

Preoperative Anemia as a Prognostic Factor in Endometrioid-Type Endometrial Carcinoma.

J Obstet Gynaecol Can 2018 Nov;40(11):1393-1400

Department of Surgery, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia; Department of Obstetrics and Gynecology, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia. Electronic address:

Objective: This study sought to determine the frequency of preoperative anemia (hemoglobin level <12 g/dL) and its prognostic significance for clinicopathological factors and survival outcomes in Saudi patients with endometrioid-type endometrial carcinoma (EC).

Methods: A retrospective cross-sectional study was conducted at King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia. A total of 148 patients who underwent staging surgery for primary EC were retrospectively analyzed for perioperative details regarding clinicopathological factors and survival. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S17012163183039
Publisher Site
http://dx.doi.org/10.1016/j.jogc.2018.05.005DOI Listing
November 2018
13 Reads

Silibinin inhibits endometrial carcinoma via blocking pathways of STAT3 activation and SREBP1-mediated lipid accumulation.

Life Sci 2019 Jan 16;217:70-80. Epub 2018 Nov 16.

Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, PR China. Electronic address:

Aims: To seek new conservative treatments for young women with early-stage endometrial carcinoma (EC) who desire to retain fertility, we investigated the effects and the underlying mechanism of silibinin in EC, which exhibits promising anti-cancer and tumour-suppressing properties in many malignant tumours.

Main Methods: Through relevant experiments such as MTT assay, cell colony formation assay and subcutaneous xenograft experiment, we showed that silibinin inhibited the proliferation of EC cells and tumours. Silibinin significantly induced cell cycle arrest and promoted apoptosis in vitro. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00243205183075
Publisher Site
http://dx.doi.org/10.1016/j.lfs.2018.11.037DOI Listing
January 2019
8 Reads

[Diagnosis and Treatment of MSI-H Cancer in Gynecological Cancer].

Gan To Kagaku Ryoho 2018 Nov;45(11):1577-1581

Dept. of Obstetrics and Gynecology, Faculty of Life Science, Kumamoto University.

Among gynecological cancers, microsatellite instability(MSI)is most commonly found in endometrial carcinoma. When an allelic variation is observed in multiple microsatellite regions, it is called MSI-high(MSI-H). Hereditary MSI-H endometrial cancer develops through a germline mutation ofthe mismatch repair(MMR)gene, resulting in Lynch syndrome, and increased risk ofsporadic MSI-H endometrial cancer is caused by somatic lineage mutations or methylation abnormalities. Read More

View Article

Download full-text PDF

Source
November 2018
9 Reads

Malignant endometrial polyp in woman with the levonorgestrel intrauterine system - a case report.

Gynecol Endocrinol 2018 Nov 19:1-3. Epub 2018 Nov 19.

a Department of Obstetrics and Gynecology , First Medical Faculty of Charles University and General Faculty Hospital , Praha , Czech Republic.

The levonorgestrel-releasing intrauterine system (LNG-IUS) is widely used and recommended as a reliable contraceptive. It also acts by opposing the effects of estrogen on the endometrium, thereby preventing development of endometrial hyperplasia and its possible malignant transformation. This case describes a 52-year-old multiparous amenorrhoeic patient who was seen in the gynecology outpatient department for a routine control 46 months after the insertion LNG-IUS as contraception. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/09513590.2018.1
Publisher Site
http://dx.doi.org/10.1080/09513590.2018.1491028DOI Listing
November 2018
14 Reads

High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.

Hum Pathol 2018 Nov 15. Epub 2018 Nov 15.

Department of Obstetrics and Gynecology, Shimane University School of Medicine.

Synchronous endometrial and ovarian carcinomas (SEOs) represent 5% to 10% of endometrial or ovarian carcinomas. We assessed genetic alterations (in PTEN, CTNNB1, POLE, etc.) and evaluated correlations with patient outcomes to determine the utility of clonality analyses for differentiating between metastases and concurrent primary tumors and for determining whether genetic alterations in synchronous tumors are predictive of biological behavior. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00468177183042
Publisher Site
http://dx.doi.org/10.1016/j.humpath.2018.11.001DOI Listing
November 2018
8 Reads

Knockdown of long non-coding HOTAIR enhances the sensitivity to progesterone in endometrial cancer by epigenetic regulation of progesterone receptor isoform B.

Cancer Chemother Pharmacol 2019 Feb 15;83(2):277-287. Epub 2018 Nov 15.

Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

Purpose: Progesterone, particularly medroxyprogesterone acetate (MPA) has been mainly used for young endometrial carcinoma (EC) patients with conservative treatment. However, its treatment benefits are limited by insensitivity or acquired resistance. In this study, we aim to investigate the effect of long non-coding RNA HOTAIR on progesterone sensitivity in endometrial cancer, as well as the underlying mechanisms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-018-3727-0DOI Listing
February 2019
9 Reads

Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma.

Clin Cancer Res 2019 Jan 15;25(1):334-345. Epub 2018 Nov 15.

Center for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.

Purpose: Amplification of , encoding the PI3K catalytic subunit alpha, is common in uterine corpus endometrial carcinoma (UCEC) and linked to an aggressive phenotype. However, it is unclear whether amplification acts via PI3K activation. We investigated the association between amplification, markers of PI3K activity, and prognosis in a large cohort of UCEC specimens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-0452DOI Listing
January 2019
1 Read

The role of hormonal therapy in patients with uterine carcinoma.

Ceska Gynekol Fall 2018;83(4):263-270

Objective: The aim of the study was to describe the role of hormonal therapy in the treatment of malignant uterine tumors, indications, the effect of the treatment and to verify its safety in our study cohort. We also present an overview of recent studies on that topic.

Design: Unicentric retrospective observational study and review of recent literature. Read More

View Article

Download full-text PDF

Source
January 2019
6 Reads

Risk-based stratification of carcinomas concurrently involving the endometrium and ovary.

Gynecol Oncol 2019 01 6;152(1):38-45. Epub 2018 Nov 6.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address:

Objective: Determining whether carcinomas concurrently involving endometrium and ovary are independent primary tumors (IPTs) or endometrial carcinomas with ovarian metastases (at least stage IIIA endometrial cancers, IIIA-EC) using clinicopathologic criteria is often challenging. Recent genomic studies showed that most such tumors are clonally related. We sought to identify clinicopathologic features associated with clinical outcomes, and to separate women with these tumors into clinically low-risk and high-risk groups. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258183131
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2018.10.033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321787PMC
January 2019
13 Reads

Bu Shen Yang Xue Prescription Has Treating Effect on Endometrial Cancer through FSH/PI3K/AKT/Gankyrin/HIF-/cyclinD 1 Pathway in Ishikawa Cells.

Evid Based Complement Alternat Med 2018 9;2018:8412984. Epub 2018 Oct 9.

Department of Obstetrics and Gynecology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, Zhejiang Province, China.

The formulation of Bu Shen Yang Xue (BSYX) has been clinically used in treating gynecologic disease in China, especially for the development of the endometrium. Endometrial carcinoma is the most common malignant tumor of the female genital tract in developed countries. And few studies have been reported on the antitumor activity of BSYX. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/ecam/2018/8412984/
Publisher Site
http://dx.doi.org/10.1155/2018/8412984DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198581PMC
October 2018
11 Reads

Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer.

PLoS One 2018 1;13(11):e0206665. Epub 2018 Nov 1.

Computational Biology Unit, Department of Informatics, University of Bergen, Bergen, Norway.

We have identified nine highly connected and differentially expressed gene subnetworks between aggressive primary tumors and metastatic lesions in endometrial carcinomas. We implemented a novel pipeline combining gene set and network approaches, which here allows integration of protein-protein interactions and gene expression data. The resulting subnetworks are significantly associated with disease progression across tumor stages from complex atypical hyperplasia, primary tumors to metastatic lesions. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0206665PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211718PMC
November 2018
5 Reads

Mismatch Repair Protein Expression in Endometrioid Intraepithelial Neoplasia/Atypical Hyperplasia: Should We Screen for Lynch Syndrome in Precancerous Lesions?

Int J Gynecol Pathol 2018 Oct 31. Epub 2018 Oct 31.

Departments of Pathology (E.L., H.C., K.M., D.H.C., G.R.C., L.L., S.H., J.T., W.Z.) Obstetrics and Gynecology (J.L., D.S.M., W.Z.) Harold C. Simmons Comprehensive Cancer Center (E.L., D.H.C, J.L., D.S.M., W.Z.), UTSW Medical Center, Dallas, Texas.

Screening for Lynch syndrome (LS) is routinely performed in patients with endometrial carcinoma. Currently, no screening recommendations exist for LS in precancerous lesions. The study goal was to determine the incidence of abnormal protein expression in endometrioid intraepithelial neoplasia/atypical hyperplasia (EIN/AH). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PGP.0000000000000557DOI Listing
October 2018
2 Reads